磷酸二酯酶在心力衰竭治疗中的研究进展

Progress in the study of cyclic nucleotide phosphodiesterases for heart failure treatment

心力衰竭是心血管疾病发展的最终阶段,因而针对心力衰竭的精准治疗策略意义重大。环磷酸腺苷(cAMP)和环磷酸鸟苷(cGMP)是调节信号转导的第二信使,它们在心脏和心肌细胞活动中有着重要意义。磷酸二酯酶(PDEs)是一组分布和功能各具特点的水解酶,它们能够有效调节cAMP和cGMP的浓度进而干预细胞活动。PDE3和PDE5的抑制剂是现在临床常用的针对心血管疾病治疗用药,对于它们的临床和基础研究不断更新。随着人们对这些PDEs功能和药理价值不断深入的探索,我们会对相应的心衰治疗策略有更加深入的认识,与此同时,了解这些研究的进展能够帮助我们洞悉心衰治疗的策略以及正性肌力药的发展方向。

Heart failure is the final stage of cardiovascular disease development,and heart failure treatment strategies need to be explored. Cyclic adenosine monophosphate(cAMP) and cyclic guanosine monophosphate(cGMP)are second messengers that regulate signal transduction,which are hydrolyzed by a group of distributed and functional specific phosphodiesterases(PDEs) in cardiomyocytes,which play key roles in the pathogenesis of normal cell activity and heart failure. The efficacy of PDE3 and PDE5 inhibitors has been clinically recognized,and clinical and basic researches are constantly updating for their mechanisms of action. Here we summarize these research advances,which in turn helps us to understand the strategies and research directions of heart failure treatment.